A pivotal study, known as MARIPOSA, comparing osimertinib to the combination of amivantamab and lazertinib for previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC) was published on January 1, 2024. The publication details the findings from this study, which investigated these therapies in locally advanced or metastatic NSCLC.
Background
The MARIPOSA study investigated treatment options for locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations. This publication details a comparison between osimertinib and a combination therapy of amivantamab plus lazertinib in this specific patient population.
Trial design
The MARIPOSA study, titled "A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer," compared amivantamab and lazertinib combination therapy against osimertinib. The study focused on patients with locally advanced or metastatic non-small cell lung cancer.
What this means
The publication of the MARIPOSA study provides clinicians and researchers with data comparing osimertinib to the combination of amivantamab and lazertinib for previously untreated EGFR-mutated advanced NSCLC. This information is crucial for guiding treatment decisions and understanding the relative efficacy and safety profiles of these therapeutic approaches in this specific patient population.
Source
The results were published in a medical journal, as indexed by PubMed, on January 1, 2024. The article, titled "Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC," is available on pubmed.ncbi.nlm.nih.gov.